Giorgia Timon1, Barbara Alicja Jereczek-Fossa2,3, Sergio Fersino4, Cinzia Iotti5, Renzo Corvò6, Stefano Maria Magrini7, Filippo Alongi8,9. 1. Radioterapia Oncologica, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy. giorgiatimon@gmail.com. 2. Divisione di Radioterapia, IEO Istituto Europeo di Oncologia IRCCS, Milan, Italy. 3. Dipartimento di Oncologia ed Emato-oncologia, Università degli Studi di Milano, Milan, Italy. 4. Radioterapia Oncologica, Ospedale Santa Chiara di Trento, Trento, Italy. 5. Radioterapia Oncologica, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy. 6. Dipartimento di Radioterapia Oncologica, IRCCS Policlinico San Martino e Università degli Studi di Genova, Genoa, Italy. 7. Dipartimento di Radioterapia Oncologica, Università e Spedali Civili di Brescia, Brescia, Italy. 8. UOC Radioterapia Oncologica, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, VR, Italy. 9. Università di Brescia, Brescia, Italy.
Abstract
AIMS: The purpose of this survey was to investigate the current opinion among Italian radiation oncologists regarding the non-palliative radiotherapy in ab initio oligometastatic prostate cancer (OMPC) patients. METHODS: A link to complete the survey was sent via e-mail to Italian radiation oncologists on February 2018. It was requested that only one physician per facility completed the survey, and that he/she was dedicated to PC management in his/her daily clinical practice. The questionnaire consisted of 15 questions concerning the management of OMPC. RESULTS: One hundred and eleven radiation oncologists filled in the questionnaire. The majority of them see ≤ 10 patients affected by OMPC in a year. More than 80% of respondents would perform radiotherapy (RT) to both the prostate and all metastases sites, but mostly up to 2-3 metastases; furthermore, > 80% of physicians would perform RT on both nodal and bone secondary lesions. Most respondents deem a choline- or prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) mandatory before considering a patient affected by OMPC for non-palliative RT. The association of RT with androgen deprivation therapy for at least 12 months would be recommended by > 50% of respondents. In the follow-up phase, the majority would suggest a clinical examination and PSA every 3-6 months and a choline- or PSMA-PET only at biochemical progression. More than 90% of respondents confirmed to be interested in participating in a multicentre study regarding this subject. CONCLUSIONS: This survey investigated the current opinion of Italian radiation oncologists and confirmed their interest in OMPC management.
AIMS: The purpose of this survey was to investigate the current opinion among Italian radiation oncologists regarding the non-palliative radiotherapy in ab initio oligometastatic prostate cancer (OMPC) patients. METHODS: A link to complete the survey was sent via e-mail to Italian radiation oncologists on February 2018. It was requested that only one physician per facility completed the survey, and that he/she was dedicated to PC management in his/her daily clinical practice. The questionnaire consisted of 15 questions concerning the management of OMPC. RESULTS: One hundred and eleven radiation oncologists filled in the questionnaire. The majority of them see ≤ 10 patients affected by OMPC in a year. More than 80% of respondents would perform radiotherapy (RT) to both the prostate and all metastases sites, but mostly up to 2-3 metastases; furthermore, > 80% of physicians would perform RT on both nodal and bone secondary lesions. Most respondents deem a choline- or prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) mandatory before considering a patient affected by OMPC for non-palliative RT. The association of RT with androgen deprivation therapy for at least 12 months would be recommended by > 50% of respondents. In the follow-up phase, the majority would suggest a clinical examination and PSA every 3-6 months and a choline- or PSMA-PET only at biochemical progression. More than 90% of respondents confirmed to be interested in participating in a multicentre study regarding this subject. CONCLUSIONS: This survey investigated the current opinion of Italian radiation oncologists and confirmed their interest in OMPC management.
Authors: Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; F Zattoni; Nicolas Mottet Journal: Eur Urol Date: 2013-10-06 Impact factor: 20.096
Authors: Raymond Miralbell; Stephen A Roberts; Eduardo Zubizarreta; Jolyon H Hendry Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-15 Impact factor: 7.038
Authors: Laura Evangelista; Fabio Zattoni; Andrea Guttilla; Giorgio Saladini; Filiberto Zattoni; Patrick M Colletti; Domenico Rubello Journal: Clin Nucl Med Date: 2013-05 Impact factor: 7.794
Authors: Raj Kurpad; William Kim; W Kim Rathmell; Paul Godley; Young Whang; Julia Fielding; LuAnn Smith; Ava Pettiford; Heather Schultz; Matthew Nielsen; Eric M Wallen; Raj S Pruthi Journal: Urol Oncol Date: 2009-07-03 Impact factor: 3.498
Authors: Brindha Pillay; Addie C Wootten; Helen Crowe; Niall Corcoran; Ben Tran; Patrick Bowden; Jane Crowe; Anthony J Costello Journal: Cancer Treat Rev Date: 2015-11-24 Impact factor: 12.111